Filing Flows › Medpace Holdings (MEDP) › Q3 2026 › vs Q2 2026
Medpace Holdings (MEDP) Q3 2026 vs Q2 2026 (quarter over quarter)
Medpace Holdings's revenue rose $8.7M (+1%) from $707M in Q2 2026 to $716M in Q3 2026. The biggest changes: Metabolic +$20.6M (+10%); Other −$9.8M (-4%); AVAI −$6.0M (-16%). Operating margin 23.1% against 20.8% (+2.4 pts).
Medpace Holdings, Q3 2026: revenue $716M (+8% year over year), operating margin 23.1%, net earnings $137M, operating cash flow $217M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 23.1% | 20.8% | +2.4 pts |
| Net margin | 19.2% | 17.2% | +2.0 pts |
| Free cash flow margin | 27.4% | 19.5% | +7.9 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Metabolic | $230M | $209M | $20.6M | +10% |
| Other | $209M | $219M | −$9.8M | -4% |
| Oncology | $100M | $98.3M | $1.7M | +2% |
| Cardiology | $83.6M | $82.9M | $791K | +1% |
| Central Nervous System | $61.4M | $60.0M | $1.4M | +2% |
| AVAI | $31.8M | $37.8M | −$6.0M | -16% |
| Revenue | $716M | $707M | $8.7M | +1% |
| Other income, net | $5.4M | $4.8M | $527K | +11% |
| Operating profit | $166M | $147M | $18.7M | +13% |
| Costs & expenses | $550M | $561M | −$10.0M | -2% |
| Pre-tax earnings | $171M | $152M | $19.2M | +13% |
| SG&A | $51.8M | $48.1M | $3.7M | +8% |
| Other operating costs | $499M | $512M | −$13.7M | -3% |
| Net earnings | $137M | $121M | $16.1M | +13% |
| Income tax | $33.4M | $30.3M | $3.1M | +10% |
| Depreciation & amortization | $6.6M | $6.7M | −$130K | -2% |
| Share-based compensation | $7.6M | $4.3M | $3.3M | +75% |
| Working capital & other | $65.0M | $29.6M | $35.4M | +120% |
| Operating cash flow | $217M | $162M | $54.6M | +34% |
| Free cash flow (OCF − capex) | $196M | $138M | $58.3M | +42% |
| Capital expenditures | $20.2M | $23.9M | −$3.8M | -16% |
Questions
How much did Medpace Holdings's revenue grow quarter over quarter in Q3 2026?
Medpace Holdings's revenue rose $8.7M (+1%) from $707M in Q2 2026 to $716M in Q3 2026.
What drove Medpace Holdings's revenue change in Q3 2026?
Metabolic +$20.6M (+10%); Other −$9.8M (-4%); AVAI −$6.0M (-16%).